Skip to main content

Edwards Lifesciences Corp(EW-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

DATA FROM BENCHMARK REGISTRY DEMONSTRATE IMPROVED TAVR EFFICIENCY WITH PRESERVED PATIENT SAFETY

PR Newswire - Wed May 17, 2023

PARIS, May 17, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) announced today that new data from the Benchmark Registry in Europe demonstrated the safety and effectiveness of this streamlined treatment pathway for patients receiving transcatheter aortic valve replacement (TAVR) with balloon-expandable valves. The data were presented in a late-breaking clinical data session at EuroPCR 2023.

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe